Comparative Pharmacology
Head-to-head clinical analysis: A METHAPRED versus DEXACEN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A METHAPRED versus DEXACEN 4.
A-METHAPRED vs DEXACEN-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
None Documented
None Documented
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Category C
Category C
Corticosteroid
Corticosteroid